Download PDF
Am J Perinatol 2017; 34(13): 1312-1317
DOI: 10.1055/s-0037-1603509
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Serum Endocan Level as a Predictive Marker for Hemodynamically Significant Patent Ductus Arteriosus in Very Low Birth Weight İnfants

Halit Halil
1   Division of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey
,
Cuneyt Tayman
1   Division of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey
,
Ufuk Cakır
1   Division of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey
,
Mehmet Buyuktiryaki
1   Division of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey
,
Utku Serkant
2   Department of Biochemistry, Golbası Public Hospital, Ankara, Turkey
,
Serife Suna Oğuz
1   Division of Neonatology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey
› Author Affiliations
Further Information

Publication History

15 February 2017

24 April 2017

Publication Date:
22 May 2017 (online)

    Permissions and Reprints

Abstract

Background Diagnosis and treatment of patent ductus arteriosus (PDA) in premature infants is still an important problem for clinicians. Echocardiography is the gold standard for determination of PDA based on clinical and hemodynamic significance. Clinical decision making may be aided by measuring circulating biomarkers such as natriuretic and endothelial propeptides. We aimed to investigate the significance of serum endocan and B-type natriuretic peptide (BNP) in the diagnosis and follow-up of hemodynamically significant PDA (hsPDA) in very low birth weight infants.

Materials and Methods In this study, 84 premature infants with gestation age less than 32 weeks were included. Forty-two premature infants with hsPDA were determined as the study group and 42 premature infants without PDA were assigned as the control group. Blood samples were collected and analyzed for serum endocan and pro-BNP levels.

Results Serum levels of pro-BNP and endocan in the study group at the time of diagnosis of PDA were found to be significantly higher than the control group, and the levels decreased significantly after medication. Multivariate regression analysis showed that birth weight and the presence of PDA were significantly correlated with serum endocan levels. The cutoff values of pro-BNP and endocan for PDA prediction were 290 pg/mL and 506 ng/mL, respectively.

Conclusion Endocan and pro-BNP assays have clinical importance in the diagnosis, initiation therapy, and follow response to therapy in very low birth weight infants with hsPDA.

Keywords

endocan - pro-BNP - patent ductus arteriosus - biomarkers - preterm neonates
 

  • References

  • 1 Jain A, Shah PS. Diagnosis, evaluation, and management of patent ductus arteriosus in preterm neonates. JAMA Pediatr 2015; 169 (09) 863-872
    CrossrefPubMedGoogle Scholar
  • 2 Sasi A, Deorari A. Patent ductus arteriosus in preterm infants. Indian Pediatr 2011; 48 (04) 301-308
    CrossrefPubMedGoogle Scholar
  • 3 Heuchan AM, Clyman RI. Managing the patent ductus arteriosus: current treatment options. Arch Dis Child Fetal Neonatal Ed 2014; 99 (05) F431-F436
    CrossrefPubMedGoogle Scholar
  • 4 Kulkarni M, Gokulakrishnan G, Price J, Fernandes CJ, Leeflang M, Pammi M. Diagnosing significant PDA using natriuretic peptides in preterm neonates: a systematic review. Pediatrics 2015; 135 (02) e510-e525
    CrossrefPubMedGoogle Scholar
  • 5 Buddhe S, Dhuper S, Kim R. , et al. NT-proBNP levels improve the ability of predicting a hemodynamically significant patent ductus arteriosus in very low-birth-weight infants. J Clin Neonatol 2012; 1 (02) 82-86
    CrossrefPubMedGoogle Scholar
  • 6 Lee JH, Shin JH, Park KH, Rhie YJ, Park MS, Choi BM. Can early B-type natriuretic peptide assays predict symptomatic patent ductus arteriosus in extremely low birth weight infants?. Neonatology 2013; 103 (02) 118-122
    CrossrefPubMedGoogle Scholar
  • 7 Kali A, Shetty KS. Endocan: a novel circulating proteoglycan. Indian J Pharmacol 2014; 46 (06) 579-583
    CrossrefPubMedGoogle Scholar
  • 8 Palmiere C, Augsburger M. Endocan measurement for the postmortem diagnosis of sepsis. Leg Med (Tokyo) 2014; 16 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 9 Chang X, Bian Y, Wu Y, Huang Y, Wang K, Duan T. Endocan of the maternal placenta tissue is increased in pre-eclampsia. Int J Clin Exp Pathol 2015; 8 (11) 14733-14740
    PubMedGoogle Scholar
  • 10 Kiral E, Dinleyici EC, Bozkurt-Turhan A, Bor O, Akgun Y, Akgun NA. Serum endocan levels in children with febrile neutropenia. Hematol Rep 2016; 8 (01) 6110 . Doi: 10.4081/hr.2016.6110
    PubMedGoogle Scholar
  • 11 Kose M, Emet S, Akpinar TS. , et al. Serum endocan level and the severity of coronary artery disease: a pilot study. Angiology 2015; 66 (08) 727-731
    CrossrefPubMedGoogle Scholar
  • 12 Afsar B, Takir M, Kostek O, Covic A, Kanbay M. Endocan: a new molecule playing a role in the development of hypertension and chronic kidney disease?. J Clin Hypertens (Greenwich) 2014; 16 (12) 914-916
    CrossrefPubMedGoogle Scholar
  • 13 Yang J, Yang Q, Yu S, Zhang X. Endocan: a new marker for cancer and a target for cancer therapy. Biomed Rep 2015; 3 (03) 279-283
    CrossrefPubMedGoogle Scholar
  • 14 Ballard JL, Khoury JC, Wedig K, Wang L, Eilers-Walsman BL, Lipp R. New Ballard score, expanded to include extremely premature infants. J Pediatr 1991; 119 (03) 417-423
    CrossrefPubMedGoogle Scholar
  • 15 Gitto E, Karbownik M, Reiter RJ. , et al. Effects of melatonin treatment in septic newborns. Pediatr Res 2001; 50 (06) 756-760
    CrossrefPubMedGoogle Scholar
  • 16 Gonzalez A, Sosenko IR, Chandar J, Hummler H, Claure N, Bancalari E. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr 1996; 128 (04) 470-478
    CrossrefPubMedGoogle Scholar
  • 17 Sarikabadayi YU, Aydemir O, Ozen ZT. , et al. Screening for retinopathy of prematurity in a large tertiary neonatal intensive care unit in Turkey: frequency and risk factors. Ophthalmic Epidemiol 2011; 18 (06) 269-274
    CrossrefPubMedGoogle Scholar
  • 18 Jim WT, Chiu NC, Chen MR. , et al. Cerebral hemodynamic change and intraventricular hemorrhage in very low birth weight infants with patent ductus arteriosus. Ultrasound Med Biol 2005; 31 (02) 197-202
    CrossrefPubMedGoogle Scholar
  • 19 Grosfeld JL, Chaet M, Molinari F. , et al. Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin. Ann Surg 1996; 224 (03) 350-355 , discussion 355–357
    CrossrefPubMedGoogle Scholar
  • 20 Janz-Robinson EM, Badawi N, Walker K, Bajuk B, Abdel-Latif ME. ; Neonatal Intensive Care Units Network. Neurodevelopmental outcomes of premature infants treated for patent ductus arteriosus: a population-based cohort study. J Pediatr 2015; 167 (05) 1025-32.e3
    CrossrefPubMedGoogle Scholar
  • 21 Freeman-Ladd M, Cohen JB, Carver JD, Huhta JC. The hemodynamic effects of neonatal patent ductus arteriosus shunting on superior mesenteric artery blood flow. J Perinatol 2005; 25 (07) 459-462
    CrossrefPubMedGoogle Scholar
  • 22 Mehta S, Younoszai A, Pietz J, Achanti B. Pharmacological closure of the patent ductus arteriosus. Images Paediatr Cardiol 2003; 5 (01) 1-15
    Google Scholar
  • 23 Berger MM, Hesse C, Dehnert C. , et al. Hypoxia impairs systemic endothelial function in individuals prone to high-altitude pulmonary edema. Am J Respir Crit Care Med 2005; 172 (06) 763-767
    CrossrefPubMedGoogle Scholar
  • 24 Gomez-Pomar E, Makhoul M, Westgate PM. , et al. Relationship between perfusion index and patent ductus arteriosus in preterm infants. Pediatr Res 2017; 81 (05) 775-779
    CrossrefPubMedGoogle Scholar
  • 25 Sung SI, Chang YS, Chun JY. , et al. Mandatory closure versus nonintervention for patent ductus arteriosus in very preterm infants. J Pediatr 2016; 177: 66-71.e1
    CrossrefPubMedGoogle Scholar
  • 26 Zhang SM, Zuo L, Zhou Q. , et al. Expression and distribution of endocan in human tissues. Biotech Histochem 2012; 87 (03) 172-178
    CrossrefPubMedGoogle Scholar
  • 27 Yilmaz MI, Siriopol D, Saglam M. , et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int 2014; 86 (06) 1213-1220
    CrossrefPubMedGoogle Scholar